MultiPulse Therapy (MPT) for AF (US)

Inclusion Criteria:

1. Male or female between 18 and 80 years of age
2. Willing and able to comply with the study protocol, provide a written informed consent
3. Currently indicated for atrial catheter ablation due to paroxysmal or early persistentatrial fibrillation
4. Current treatment and compliance with standard anticoagulation regimen, includinguninterrupted OAC, with acceptable coagulation status, as determined by the PrincipalInvestigator

Exclusion Criteria: The subject must not meet any of the following exclusion criteria:

1. Life expectancy of 1 year or less
2. AF due to reversible causes (e.g., hyperthyroidism, valve disease)
3. History of DC Cardioversion which failed to convert to AF to Normal Sinus Rhythm
4. Currently in AF for more than 3 months continuously
5. Chronic, long-standing persistent, or permanent atrial fibrillation
6. Allergy or contraindication to anticoagulation therapy
7. Presence of intracardiac thrombus (confirmed with TEE or ICE)
8. Existing Left Atrial Appendage closure device
9. Severely Dilated Left Atrium >5cm
10. LVEF<35%
11. NYHA Class III or IV heart failure at the time of enrollment
12. History of embolic stroke, Transient Ischemic Attack (TIA) or other thromboembolicevent within the preceding 3 months.
13. Known hyper-coagulable state that increases risk of thrombus
14. History of myocardial infarction or coronary revascularization within the preceding 3months.
15. History of sustained ventricular arrhythmia or cardiac arrest
16. Presence of chronically implanted lead in the CS
17. Presence of ventricular assist device, including intra-aortic balloon pump
18. Documented bradycardia (<40 BPM) at the time of the study
19. Morbid obesity: BMI>39 kg/m2
20. Presence of any prosthetic cardiac valve
21. History of significant tricuspid valvular disease requiring surgery
22. Moderate to severe mitral valve regurgitation (>40% regurgitation fraction)
23. Cognitive or mental health status that would interfere with study participation andproper informed consent
24. Cardiovascular anatomical defects that would complicate placement of the stimulationleads required by the protocol, including congenital heart disease and cardiac veinanomalies per the Investigator's discretion
25. Pregnancy confirmed by test within 7 days of procedure.
26. Inability to pass catheters to heart due to vascular limitations
27. Cardiovascular surgery or intervention within 1 month prior to enrollment or plannedfor up to 1 month after enrollment (other than the planned treatment procedure)
28. Active endocarditis
29. Any other medical condition which may affect the outcome of this study or safety ofthe subject as determined by the investigator
30. History of hemodynamic compromise due to valvular heart disease
31. Unstable CAD as determined by the investigator
32. Severe proximal three-vessel or left main coronary artery disease withoutrevascularization as determined by the investigator
33. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,Congenital Heart Anomaly, Cardiac Amyloidosis or Cardiac Sarcoidosis